Review of two immunosuppressants: tacrolimus and cyclosporine
Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and s...
Saved in:
| Published in | Journal of the Korean Association of Oral and Maxillofacial Surgeons Vol. 49; no. 6; pp. 311 - 323 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Association of Oral and Maxillofacial Surgeons
31.12.2023
대한구강악안면외과학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2234-7550 2234-5930 |
| DOI | 10.5125/jkaoms.2023.49.6.311 |
Cover
| Abstract | Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: "transplantation immunosuppressant," "cyclosporine," "tacrolimus," "calcineurin inhibitor (CNI)," "efficacy," "safety," "induction therapy," "maintenance therapy," and "conversion therapy." Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required. |
|---|---|
| AbstractList | Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: “transplantation immunosuppressant,” “cyclosporine,” “tacrolimus,” “calcineurin inhibitor (CNI),” “efficacy,” “safety,” “induction therapy,” “maintenance therapy,” and “conversion therapy.” Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required. Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: “transplantation immunosuppressant,” “cyclosporine,” “tacrolimus,” “calcineurin inhibitor (CNI),” “efficacy,” “safety,” “induction therapy,” “maintenance therapy,” and “conversion therapy.” Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required. KCI Citation Count: 0 Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: "transplantation immunosuppressant," "cyclosporine," "tacrolimus," "calcineurin inhibitor (CNI)," "efficacy," "safety," "induction therapy," "maintenance therapy," and "conversion therapy." Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required.Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review article was prepared to compare the two most used immunosuppressants, cyclosporine and tacrolimus, in terms of mechanism of action, efficacy, and safety and to assess recent trials to mitigate their side effects. PubMed and Google Scholar queries were conducted using combinations of the following search terms: "transplantation immunosuppressant," "cyclosporine," "tacrolimus," "calcineurin inhibitor (CNI)," "efficacy," "safety," "induction therapy," "maintenance therapy," and "conversion therapy." Both immunosuppressants inhibit calcineurin and effectively down-regulate cytokines. Tacrolimus may be more advantageous since it lowers the likelihood of acute rejection, has the ability to reverse allograft rejection following cyclosporine treatment, and has the potential to reinnervate nerves. Meanwhile, graft survival rates seem to be comparable for the CNIs. To avoid nephrotoxicity, various immunosuppressants other than CNIs have been studied. Despite averting nephrotoxicity, these medications show increases in acute rejection or other types of adverse effects compared to CNIs. FT has been a topic of interest for oral and maxillofacial surgeons, and the postoperative usage of immunosuppressants is crucial for the long-term prognosis of FT. As contemporary transplantation regimens incorporate novel medications along with CNIs, further research is required. |
| Author | Kim, Soung Min Myoung, Hoon Lee, HyunJong |
| AuthorAffiliation | Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea |
| AuthorAffiliation_xml | – name: Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: HyunJong orcidid: 0000-0003-4700-2137 surname: Lee fullname: Lee, HyunJong organization: Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea – sequence: 2 givenname: Hoon orcidid: 0000-0002-9984-8479 surname: Myoung fullname: Myoung, Hoon organization: Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea – sequence: 3 givenname: Soung Min orcidid: 0000-0002-6916-0489 surname: Kim fullname: Kim, Soung Min organization: Department of Oral and Maxillofacial Surgery, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38155084$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003028403$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kVtLJDEQhcPisro6_0CkH2Vh2ly7O4LIIHsZEARxn0M6U61xupM26Xbw32_mssPqw-alAvWdU0Wdr-jAeQcInRKcC0LFxfNS-y7mFFOWc5kXOSPkEzqilPGpkAwf7P6lEPgQTWJ8xukVtGQl_YIOWUVSo-JH6OoeXi2sMt9kw8pntutG5-PY9wFi1G6Il9mgTfCt7caYabfIzJtpfex9sA5O0OdGtxEmu3qMfv_4_nDza3p793N-M7udGs75MCVgKoabUtYlNFJQSUCaWgPQtEVDRC1qbKSWRYOBkoXBjFWFZDUwzSUTFTtG37a-LjRqaazy2m7qo1fLoGb3D3NFMCskKVmCr7dwP9YdLAy4IehW9cF2OrxtpO87zj4lo9fkUBaEkbXD-c4h-JcR4qA6Gw20rXbgx6ioxFVKgYsioWf_DttP-XvhBPAtkI4YY4BmjxCs1lmqbZZqnaXiUhUqZZlklx9kxg56sH69sm3_L_4D79ynHA |
| CitedBy_id | crossref_primary_10_1016_j_lfs_2024_122995 crossref_primary_10_1097_JS9_0000000000002001 crossref_primary_10_3390_ijms25179732 crossref_primary_10_4081_ejtm_2025_13203 crossref_primary_10_3390_fermentation10120645 crossref_primary_10_3390_biology13090744 crossref_primary_10_3390_cimb47010002 crossref_primary_10_3390_ijms26062711 crossref_primary_10_3390_pharmaceutics16121487 crossref_primary_10_1016_j_ajoc_2025_102256 crossref_primary_10_1016_j_trim_2024_102147 crossref_primary_10_2147_OPTH_S476163 crossref_primary_10_3390_ph17111499 |
| Cites_doi | 10.2215/CJN.04800908 10.1002/(SICI)1097-4598(200004)23:4<633::AID-MUS24>3.0.CO;2-Q 10.1097/01.tp.0000219703.39149.85 10.1007/s001470050708 10.1111/j.1399-0012.1996.tb00458.x 10.2478/s11658-008-0041-6 10.1016/S0169-409X(97)00043-4 10.1016/j.transproceed.2017.07.013 10.1007/BF02044336 10.1097/FTD.0000000000000640 10.1016/j.jhsa.2020.03.018 10.2165/00003495-200666170-00010 10.1016/j.ymthe.2020.09.011 10.1093/ndt/gfh739 10.1097/00007890-200206150-00019 10.1016/j.eururo.2004.02.009 10.1016/j.clinre.2020.04.017 10.1016/S0021-9258(18)42176-X 10.1016/j.transproceed.2016.03.043 10.1016/j.transproceed.2019.08.039 10.1111/j.1399-0012.2006.00604.x 10.1021/acs.jmedchem.1c00580 10.1053/j.ajkd.2016.09.021 10.1111/j.1399-0012.2011.01512.x 10.1007/s13346-019-00650-1 10.2165/00003088-200443100-00001 10.1155/2011/480642 10.1056/NEJMoa067411 10.3389/fimmu.2021.663602 10.1097/01.tp.0000234905.56926.7f 10.1016/S0162-3109(00)00190-9 10.1080/08923973.2021.1966033 10.1055/s-0041-1736467 10.1016/j.ejps.2017.12.017 10.1016/S0140-6736(06)68935-6 10.1016/j.transproceed.2010.05.036 10.1016/j.fsc.2022.01.011 10.1111/aor.13551 10.1097/00000637-200207000-00015 10.5415/apallergy.2015.5.3.181 10.3390/cancers11071037 10.1097/00007890-199603150-00032 10.5500/wjt.v6.i4.697 10.1016/j.burns.2010.01.011 10.1016/j.drudis.2015.05.006 10.1097/SCS.0b013e318241b8e0 10.1016/B978-0-12-801238-3.64236-8 10.1111/ctr.13903 10.1055/s-0032-1333314 10.1111/ajt.16152 10.1016/S0140-6736(08)61277-5 10.1034/j.1399-0012.1999.130301.x 10.1681/ASN.2021050628 10.4103/2230-973X.106981 10.1038/nri2035 10.1016/j.trre.2021.100653 10.1016/S0162-3109(00)00192-2 10.3109/00207454.2014.971121 10.1016/j.intimp.2009.12.003 10.1097/00007890-199708150-00012 10.2165/00003088-200241110-00003 10.2174/1389200219666180101104159 10.1097/GOX.0000000000003586 10.1007/BF00314952 10.1080/03639040601155665 10.1007/s40265-014-0316-3 10.1111/ctr.12951 10.1016/S0039-6060(99)70181-9 10.1016/S0959-8049(01)00171-X 10.1517/14740338.2015.1040388 10.1097/00007890-200007270-00017 10.1016/S0032-9592(98)00095-8 10.2146/ajhp140322 10.1002/mus.10195 10.1517/14656566.2013.751374 10.7164/antibiotics.40.1249 10.1097/TP.0b013e31826e5995 10.1097/FPC.0b013e328364db84 10.1016/j.transproceed.2004.01.021 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved. 2023 |
| Copyright_xml | – notice: Copyright © 2023 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved. 2023 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.5125/jkaoms.2023.49.6.311 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2234-5930 |
| EndPage | 323 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10369173 PMC10761313 38155084 10_5125_jkaoms_2023_49_6_311 |
| Genre | Journal Article Review |
| GroupedDBID | 5-W 8JR 8XY 9ZL AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION EF. HYE KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM ACYCR ADRAZ KVFHK |
| ID | FETCH-LOGICAL-c444t-1ec830f79b7ef95291e9cbaee2550f15b5b0c9a96f0e21dc0338693be3a493583 |
| IEDL.DBID | M48 |
| ISSN | 2234-7550 |
| IngestDate | Sun Mar 09 07:51:20 EDT 2025 Thu Aug 21 18:42:32 EDT 2025 Fri Jul 11 01:40:32 EDT 2025 Thu Apr 03 07:04:04 EDT 2025 Thu Apr 24 22:55:08 EDT 2025 Tue Jul 01 02:03:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Immunosuppressant Cyclosporine Tacrolimus Facial transplantation Calcineurin inhibitors |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c444t-1ec830f79b7ef95291e9cbaee2550f15b5b0c9a96f0e21dc0338693be3a493583 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-9984-8479 0000-0002-6916-0489 0000-0003-4700-2137 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5125/jkaoms.2023.49.6.311 |
| PMID | 38155084 |
| PQID | 2908125456 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10369173 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10761313 proquest_miscellaneous_2908125456 pubmed_primary_38155084 crossref_primary_10_5125_jkaoms_2023_49_6_311 crossref_citationtrail_10_5125_jkaoms_2023_49_6_311 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20231231 |
| PublicationDateYYYYMMDD | 2023-12-31 |
| PublicationDate_xml | – month: 12 year: 2023 text: 20231231 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of the Korean Association of Oral and Maxillofacial Surgeons |
| PublicationTitleAlternate | J Korean Assoc Oral Maxillofac Surg |
| PublicationYear | 2023 |
| Publisher | The Korean Association of Oral and Maxillofacial Surgeons 대한구강악안면외과학회 |
| Publisher_xml | – name: The Korean Association of Oral and Maxillofacial Surgeons – name: 대한구강악안면외과학회 |
| References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref11 ref55 ref10 ref54 ref17 ref16 ref19 ref18 ref51 ref50 ref90 ref46 ref45 ref89 ref48 ref47 ref42 ref86 ref41 ref85 ref44 ref88 ref43 ref87 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref82 ref81 ref40 ref84 ref83 ref80 ref35 ref79 ref34 ref78 ref37 ref36 ref31 ref75 ref30 ref74 ref33 ref77 ref32 ref76 ref2 ref1 ref39 ref38 ref71 ref70 ref73 ref72 ref24 ref68 ref23 ref67 ref26 ref25 ref69 ref20 ref64 ref63 ref22 ref66 ref21 ref65 ref28 ref27 ref29 ref60 ref62 ref61 |
| References_xml | – ident: ref37 – ident: ref2 doi: 10.2215/CJN.04800908 – ident: ref62 doi: 10.1002/(SICI)1097-4598(200004)23:4<633::AID-MUS24>3.0.CO;2-Q – ident: ref72 doi: 10.1097/01.tp.0000219703.39149.85 – ident: ref56 doi: 10.1007/s001470050708 – ident: ref12 doi: 10.1111/j.1399-0012.1996.tb00458.x – ident: ref11 doi: 10.2478/s11658-008-0041-6 – ident: ref27 doi: 10.1016/S0169-409X(97)00043-4 – ident: ref39 doi: 10.1016/j.transproceed.2017.07.013 – ident: ref50 doi: 10.1007/BF02044336 – ident: ref40 doi: 10.1097/FTD.0000000000000640 – ident: ref16 doi: 10.1016/j.jhsa.2020.03.018 – ident: ref38 doi: 10.2165/00003495-200666170-00010 – ident: ref90 doi: 10.1016/j.ymthe.2020.09.011 – ident: ref48 doi: 10.1093/ndt/gfh739 – ident: ref51 doi: 10.1097/00007890-200206150-00019 – ident: ref57 doi: 10.1016/j.eururo.2004.02.009 – ident: ref71 doi: 10.1016/j.clinre.2020.04.017 – ident: ref4 doi: 10.1016/S0021-9258(18)42176-X – ident: ref23 doi: 10.1016/j.transproceed.2016.03.043 – ident: ref45 doi: 10.1016/j.transproceed.2019.08.039 – ident: ref70 doi: 10.1111/j.1399-0012.2006.00604.x – ident: ref8 doi: 10.1021/acs.jmedchem.1c00580 – ident: ref84 doi: 10.1053/j.ajkd.2016.09.021 – ident: ref34 – ident: ref69 doi: 10.1111/j.1399-0012.2011.01512.x – ident: ref9 doi: 10.1007/s13346-019-00650-1 – ident: ref25 doi: 10.2165/00003088-200443100-00001 – ident: ref30 – ident: ref36 – ident: ref61 – ident: ref10 doi: 10.1155/2011/480642 – ident: ref65 – ident: ref5 doi: 10.1056/NEJMoa067411 – ident: ref76 doi: 10.3389/fimmu.2021.663602 – ident: ref1 doi: 10.1097/01.tp.0000234905.56926.7f – ident: ref68 doi: 10.1016/S0162-3109(00)00190-9 – ident: ref77 doi: 10.1080/08923973.2021.1966033 – ident: ref63 doi: 10.1055/s-0041-1736467 – ident: ref17 doi: 10.1016/j.ejps.2017.12.017 – ident: ref66 doi: 10.1016/S0140-6736(06)68935-6 – ident: ref6 doi: 10.1016/j.transproceed.2010.05.036 – ident: ref88 doi: 10.1016/j.fsc.2022.01.011 – ident: ref53 doi: 10.1111/aor.13551 – ident: ref64 doi: 10.1097/00000637-200207000-00015 – ident: ref21 doi: 10.5415/apallergy.2015.5.3.181 – ident: ref33 – ident: ref44 doi: 10.3390/cancers11071037 – ident: ref35 doi: 10.1097/00007890-199603150-00032 – ident: ref47 doi: 10.5500/wjt.v6.i4.697 – ident: ref86 doi: 10.1016/j.burns.2010.01.011 – ident: ref73 doi: 10.1016/j.drudis.2015.05.006 – ident: ref89 doi: 10.1097/SCS.0b013e318241b8e0 – ident: ref78 doi: 10.1016/B978-0-12-801238-3.64236-8 – ident: ref74 doi: 10.1111/ctr.13903 – ident: ref41 – ident: ref58 doi: 10.1055/s-0032-1333314 – ident: ref83 doi: 10.1111/ajt.16152 – ident: ref67 doi: 10.1016/S0140-6736(08)61277-5 – ident: ref46 doi: 10.1034/j.1399-0012.1999.130301.x – ident: ref82 doi: 10.1681/ASN.2021050628 – ident: ref19 doi: 10.4103/2230-973X.106981 – ident: ref42 doi: 10.1038/nri2035 – ident: ref55 – ident: ref81 doi: 10.1016/j.trre.2021.100653 – ident: ref3 doi: 10.1016/S0162-3109(00)00192-2 – ident: ref59 doi: 10.3109/00207454.2014.971121 – ident: ref22 doi: 10.1016/j.intimp.2009.12.003 – ident: ref54 doi: 10.1097/00007890-199708150-00012 – ident: ref26 doi: 10.2165/00003088-200241110-00003 – ident: ref28 doi: 10.2174/1389200219666180101104159 – ident: ref87 doi: 10.1097/GOX.0000000000003586 – ident: ref29 doi: 10.1007/BF00314952 – ident: ref80 – ident: ref14 doi: 10.1080/03639040601155665 – ident: ref18 doi: 10.1007/s40265-014-0316-3 – ident: ref79 doi: 10.1111/ctr.12951 – ident: ref85 doi: 10.1016/S0039-6060(99)70181-9 – ident: ref13 doi: 10.1016/S0959-8049(01)00171-X – ident: ref75 doi: 10.1517/14740338.2015.1040388 – ident: ref32 doi: 10.1097/00007890-200007270-00017 – ident: ref7 doi: 10.1016/S0032-9592(98)00095-8 – ident: ref24 doi: 10.2146/ajhp140322 – ident: ref60 doi: 10.1002/mus.10195 – ident: ref49 doi: 10.1517/14656566.2013.751374 – ident: ref15 doi: 10.7164/antibiotics.40.1249 – ident: ref20 doi: 10.1097/TP.0b013e31826e5995 – ident: ref43 doi: 10.1097/FPC.0b013e328364db84 – ident: ref52 doi: 10.1016/j.transproceed.2004.01.021 – ident: ref31 |
| SSID | ssj0000627372 |
| Score | 2.3910701 |
| SecondaryResourceType | review_article |
| Snippet | Immunosuppressants are vital in organ transplantation including facial transplantation (FT) but are associated with persistent side effects. This review... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 311 |
| SubjectTerms | Review 치의학 |
| Title | Review of two immunosuppressants: tacrolimus and cyclosporine |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38155084 https://www.proquest.com/docview/2908125456 https://pubmed.ncbi.nlm.nih.gov/PMC10761313 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003028403 |
| Volume | 49 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 대한구강악안면외과학회지, 2023, 49(6), , pp.311-323 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fi9QwEB7OE-ReRPFX_UVFX7s2TZo2goiIxynokwv3FpJ0qnu71567XfT-e2c23cWVO3zqQ5OUfpN0vukk8wG8crUJRDRMVjQ0g5XzVeZyV2YaEUXVYI2bg8JfvuqTqfp8Wp4ewFazdQRwdWVox3pS0-Vi8vvn5Tta8MRfJ-Suytdnc9efc-ntQk6UmWiKQykeurnJGPFmvpHwx29zwbosrDhXSJVVxM_jebprBzqCW-TUqF2t9lzXjW7ZXsVK_91c-Ze3Or4Dt0eamb6P8-IuHGB3D97GREDat-nwq09nfDSkX60vog5KN6zepIMLLONzvl6lrmvScBkWPaNDXPQ-TI8_fvtwko3yCVlQSg2ZwFDLvK2Mr7A1ZWEEmuAdIkUReStKX_o8GGd0m2MhmpBTtKqN9Cid4uyofACHXd_hI0i98LpxHsmzBdU6NIIde6MrzYQwiATkFhkbxtriLHGxsBRjMLQ2QmsZWquM1ZagTSDb9bqItTX-0_4lgW7nYWa5KDZfv_d2vrRE_T9RT6kp9pQJvNgaxdJS4fyH67Bf02CG-E_BlDGBh9FIu-dubZxAvWe-XQN-4v6dbvZjU45b8K8gKeTjawd9Akf8IrE-5FM4HJZrfEZcZvDPN9PzD9DK78o |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Review+of+two+immunosuppressants%3A+tacrolimus+and+cyclosporine&rft.jtitle=Journal+of+the+Korean+Association+of+Oral+and+Maxillofacial+Surgeons&rft.au=Lee%2C+HyunJong&rft.au=Myoung%2C+Hoon&rft.au=Kim%2C+Soung+Min&rft.date=2023-12-31&rft.issn=2234-7550&rft.volume=49&rft.issue=6&rft.spage=311&rft_id=info:doi/10.5125%2Fjkaoms.2023.49.6.311&rft_id=info%3Apmid%2F38155084&rft.externalDocID=38155084 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-7550&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-7550&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-7550&client=summon |